Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

Gupta R, Cristea M, Frankel P, Ruel C, Chen C, Wang Y, Morgan R, Leong L, Chow W, Koczywas M, Koehler S, Lim D, Luu T, Martel C, McNamara M, Somlo G, Twardowski P, Yen Y, Idorenyi A, Raechelle T, Carroll M, Chung V.

Cancer Treat Res Commun. 2019 Jul 3;21:100155. doi: 10.1016/j.ctarc.2019.100155. [Epub ahead of print]

PMID:
31279962
2.

Obesity Surgery and Anesthesiology Risks: a Review of Key Concepts and Related Physiology.

Pouwels S, Buise MP, Twardowski P, Stepaniak PS, Proczko M.

Obes Surg. 2019 May 24. doi: 10.1007/s11695-019-03952-y. [Epub ahead of print] Review.

PMID:
31127496
3.

Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer.

Hsu T, Nathwani N, Loscalzo M, Chung V, Chao J, Karanes C, Koczywas M, Forman S, Lim D, Siddiqi T, Stein A, Twardowski P, Nademanee A, Pal S, Siccion E, Hein M, Akiba C, Goldstein L, Smith D, Ma H, Feng T, Hurria A.

J Am Geriatr Soc. 2019 May;67(5):978-986. doi: 10.1111/jgs.15841. Epub 2019 Mar 22.

PMID:
30901083
4.

Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer.

Hahn AW, Stenehjem DD, Alex AB, Gill DM, Cheng HH, Kessler ER, Chittoria N, Twardowski P, Vaishampayan U, Agarwal N.

Urol Oncol. 2019 Jun;37(6):352.e19-352.e24. doi: 10.1016/j.urolonc.2019.01.029. Epub 2019 Feb 13.

PMID:
30770300
5.

Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer.

Twardowski P, Wong JYC, Pal SK, Maughan BL, Frankel PH, Franklin K, Junqueira M, Prajapati MR, Nachaegari G, Harwood D, Agarwal N.

Cancer Treat Res Commun. 2019;19:100116. doi: 10.1016/j.ctarc.2018.100116. Epub 2018 Dec 20.

PMID:
30682445
6.

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107.

Twardowski PW, Tangen CM, Wu X, Plets MR, Plimack ER, Agarwal N, Vogelzang NJ, Wang J, Tao S, Thompson IM, Lara P.

Kidney Cancer. 2017 Nov 27;1(2):123-132. doi: 10.3233/KCA-170018.

7.

Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients.

Pieczonka CM, Twardowski P, Renzulli J 2nd, Hafron J, Boldt-Houle DM, Atkinson S, Eggener S.

Rev Urol. 2018;20(2):63-68. doi: 10.3909/riu0798.

8.

Chromatic analysis of harmonic Fresnel lenses by FDTD and angular spectrum methods.

Yang J, Twardowski P, Gérard P, Yu W, Fontaine J.

Appl Opt. 2018 Jul 1;57(19):5281-5287. doi: 10.1364/AO.57.005281.

PMID:
30117815
9.

Ultra-narrow photonic nanojets through a glass cuboid embedded in a dielectric cylinder.

Yang J, Twardowski P, Gérard P, Duo Y, Fontaine J, Lecler S.

Opt Express. 2018 Feb 19;26(4):3723-3731. doi: 10.1364/OE.26.003723.

PMID:
29475352
10.

Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide.

Pal SK, He M, Chen L, Yang L, Pillai R, Twardowski P, Hsu J, Kortylewski M, Jones JO.

Urol Oncol. 2018 Apr;36(4):162.e1-162.e6. doi: 10.1016/j.urolonc.2017.12.006. Epub 2017 Dec 27.

11.

Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.

Lara PN Jr, Plets M, Tangen C, Gertz E, Vogelzang NJ, Hussain M, Twardowski PW, Garzotto MG, Monk JP, Carducci M, Goldkorn A, Mack PC, Thompson I, Van Loan M, Quinn DI.

Cancer Treat Res Commun. 2018;16:18-23. doi: 10.1016/j.ctarc.2018.04.005. Epub 2018 Apr 28.

12.

Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).

Pal SK, Patel J, He M, Foulk B, Kraft K, Smirnov DA, Twardowski P, Kortylewski M, Bhargava V, Jones JO.

Cancer. 2018 Mar 15;124(6):1216-1224. doi: 10.1002/cncr.31161. Epub 2017 Dec 19.

13.

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.

Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM.

J Clin Oncol. 2018 Apr 1;36(10):991-999. doi: 10.1200/JCO.2017.75.7310. Epub 2017 Dec 20.

14.

Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.

Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV.

Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13.

PMID:
29248319
15.

Outcomes and toxicity of 313 prostate cancer patients receiving helical tomotherapy after radical prostatectomy.

Jensen L, Yuh B, Wong JYC, Schultheiss T, Cheng J, Ruel N, Twardowski P, Sampath S.

Adv Radiat Oncol. 2017 Aug 8;2(4):597-607. doi: 10.1016/j.adro.2017.08.004. eCollection 2017 Oct-Dec.

16.

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.

Bellmunt J, Eigl BJ, Senkus E, Loriot Y, Twardowski P, Castellano D, Blais N, Sridhar SS, Sternberg CN, Retz M, Pal S, Blumenstein B, Jacobs C, Stewart PS, Petrylak DP.

Ann Oncol. 2017 Oct 1;28(10):2481-2488. doi: 10.1093/annonc/mdx400.

PMID:
28961845
17.

Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.

Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN Jr, Goldkorn A, Garzotto MG, Mack PC, Higano CS, Vogelzang NJ, Thompson IM Jr, Twardowski PW, Van Veldhuizen PJ Jr, Agarwal N, Carducci MA, Monk JP, Quinn DI.

Clin Genitourin Cancer. 2017 Dec;15(6):635-641. doi: 10.1016/j.clgc.2017.05.014. Epub 2017 May 10.

18.

Commentary to the article "Neuromuscular blockade in the elderly".

Twardowski P, Domżalski M.

Anaesthesiol Intensive Ther. 2017;49(1):75-76. doi: 10.5603/AIT.2017.0012. No abstract available.

19.

Design of a large field-of-view see-through near to eye display with two geometrical waveguides.

Yang J, Twardowski P, Gérard P, Fontaine J.

Opt Lett. 2016 Dec 1;41(23):5426-5429. doi: 10.1364/OL.41.005426.

PMID:
27906204
20.

High-dynamic-range microscope imaging based on exposure bracketing in full-field optical coherence tomography.

Leong-Hoi A, Montgomery PC, Serio B, Twardowski P, Uhring W.

Opt Lett. 2016 Apr 1;41(7):1313-6. doi: 10.1364/OL.41.001313.

PMID:
27192224
21.

Evaluation of the relationship between baseline autonomic tone and the vagotonic effect of a bolus dose of remifentanil.

Wujtewicz MA, Hasak L, Twardowski P, Zabul E, Owczuk R.

Anaesthesia. 2016 Jul;71(7):823-8. doi: 10.1111/anae.13505. Epub 2016 May 6.

22.

The influence of epidural blockade on gut permeability in patients undergoing open surgical repair of abdominal aortic aneurysm.

Owczuk R, Dylczyk-Sommer A, Wojciechowski J, Paszkiewicz M, Wujtewicz M, Stepnowski P, Twardowski P, Sawicka W, Domżalski M, Wujtewicz MA.

Anaesthesiol Intensive Ther. 2016;48(2):122-7. doi: 10.5603/AIT.a2016.0014. Epub 2016 Mar 11.

23.

Implementing enhanced recovery after bariatric surgery protocol: a retrospective study.

Proczko M, Kaska L, Twardowski P, Stepaniak P.

J Anesth. 2016 Feb;30(1):170-3. doi: 10.1007/s00540-015-2089-6. Epub 2015 Oct 24.

24.

Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer.

Pal SK, Vuong W, Zhang W, Deng J, Liu X, Carmichael C, Ruel N, Pinnamaneni M, Twardowski P, Lau C, Yu H, Figlin RA, Agarwal N, Jones JO.

Mol Cancer Ther. 2015 Dec;14(12):2896-900. doi: 10.1158/1535-7163.MCT-15-0367. Epub 2015 Oct 8.

25.

A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responses.

Twardowski P, Kanaya N, Frankel P, Synold T, Ruel C, Pal SK, Junqueira M, Prajapati M, Moore T, Tryon P, Chen S.

Cancer. 2015 Sep 1;121(17):2942-50. doi: 10.1002/cncr.29421. Epub 2015 May 18.

26.

Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.

Cheng HH, Gulati R, Azad A, Nadal R, Twardowski P, Vaishampayan UN, Agarwal N, Heath EI, Pal SK, Rehman HT, Leiter A, Batten JA, Montgomery RB, Galsky MD, Antonarakis ES, Chi KN, Yu EY.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):122-7. doi: 10.1038/pcan.2014.53. Epub 2015 Jan 20.

27.

Ondansetron attenuates the decrease in blood pressure due to spinal anesthesia in the elderly: a double blind, placebo-controlled study.

Owczuk R, Wenski W, Twardowski P, Dylczyk-Sommer A, Sawicka W, Wujtewicz MA, Marciniak A, Polak-Krzemińska A, Jasiński T, Wujtewicz M.

Minerva Anestesiol. 2015 Jun;81(6):598-607.

28.

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.

Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Vogelzang NJ, Thompson IM Jr, Cote RJ, Quinn DI.

Int J Cancer. 2015 Apr 15;136(8):1856-62. doi: 10.1002/ijc.29212. Epub 2014 Oct 8.

29.

The influence of epidural anesthesia on the electrical activity of heart atria.

Twardowski P, Owczuk R, Wujtewicz MA, Wojciechowski J, Marjanski T, Marciniak A, Wujtewicz M.

Kardiochir Torakochirurgia Pol. 2014 Jun;11(2):156-61. doi: 10.5114/kitp.2014.43843. Epub 2014 Jun 29.

30.

A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.

Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC.

Cancer. 2014 Sep 1;120(17):2684-93. doi: 10.1002/cncr.28767. Epub 2014 May 6.

31.

Papillary renal cell carcinoma: current progress and future directions.

Twardowski PW, Mack PC, Lara PN Jr.

Clin Genitourin Cancer. 2014 Apr;12(2):74-9. doi: 10.1016/j.clgc.2013.11.013. Epub 2013 Nov 13. Review.

PMID:
24629521
32.

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP 3rd, Datar RH, Garzotto M, Mack PC, Lara P Jr, Higano CS, Hussain M, Thompson IM Jr, Cote RJ, Vogelzang NJ.

J Clin Oncol. 2014 Apr 10;32(11):1136-42. doi: 10.1200/JCO.2013.51.7417. Epub 2014 Mar 10.

33.

Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.

Lara PN Jr, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD.

J Natl Cancer Inst. 2014 Apr;106(4):dju013. doi: 10.1093/jnci/dju013. Epub 2014 Feb 24.

34.

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.

Quinn DI, Tangen CM, Hussain M, Lara PN Jr, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM Jr.

Lancet Oncol. 2013 Aug;14(9):893-900. doi: 10.1016/S1470-2045(13)70294-8. Epub 2013 Jul 17.

35.

A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.

Twardowski PW, Beumer JH, Chen CS, Kraft AS, Chatta GS, Mitsuhashi M, Ye W, Christner SM, Lilly MB.

Anticancer Drugs. 2013 Aug;24(7):743-53. doi: 10.1097/CAD.0b013e328361feb0.

36.

Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.

Pal SK, Hsu J, Hsu S, Hu J, Bergerot P, Carmichael C, Saikia J, Liu X, Lau C, Twardowski P, Figlin RA, Yuh BF.

J Geriatr Oncol. 2013 Apr;4(2):128-33.

37.

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies.

Weiss GJ, Chao J, Neidhart JD, Ramanathan RK, Bassett D, Neidhart JA, Choi CHJ, Chow W, Chung V, Forman SJ, Garmey E, Hwang J, Kalinoski DL, Koczywas M, Longmate J, Melton RJ, Morgan R, Oliver J, Peterkin JJ, Ryan JL, Schluep T, Synold TW, Twardowski P, Davis ME, Yen Y.

Invest New Drugs. 2013 Aug;31(4):986-1000. doi: 10.1007/s10637-012-9921-8. Epub 2013 Feb 9.

38.

Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors.

Pal SK, Yamzon J, Sun V, Carmichael C, Saikia J, Ferrell B, Frankel P, Hsu J, Twardowski P, Stein CA, Margolin K.

Clin Genitourin Cancer. 2013 Jun;11(2):121-7. doi: 10.1016/j.clgc.2012.09.007. Epub 2012 Oct 11.

39.

The influence of low flow anaesthesia on renal function in cancer patients previously treated with nephrotoxic chemotherapeutic agents.

Wujtewicz M, Sawicka W, Wenski W, Marciniak A, Wujtewicz MA, Stepnowski P, Twardowski P, Dylczyk-Sommer A, Owczuk R.

Anaesthesiol Intensive Ther. 2012 Aug 8;44(2):71-5.

40.

Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.

Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D'Amico AV, Eastham JA, Enke CA, Farrington T, Higano CS, Horwitz EM, Kantoff PW, Kawachi MH, Kuettel M, Lee RJ, MacVicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Roach M 3rd, Rohren E, Rosenfeld S, Srinivas S, Strope SA, Tward J, Twardowski P, Walsh PC, Ho M, Shead DA.

J Natl Compr Canc Netw. 2012 Sep;10(9):1081-7.

PMID:
22956807
41.

Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis.

Pal SK, Jones JO, Carmichael C, Saikia J, Hsu J, Liu X, Figlin RA, Twardowski P, Lau C.

Urol Oncol. 2013 Nov;31(8):1826-31. doi: 10.1016/j.urolonc.2012.04.007. Epub 2012 May 17.

42.
43.

Long-term survival after high-dose chemotherapy followed by peripheral stem cell rescue for high-risk, locally advanced/inflammatory, and metastatic breast cancer.

VanderWalde A, Ye W, Frankel P, Asuncion D, Leong L, Luu T, Morgan R, Twardowski P, Koczywas M, Pezner R, Paz IB, Margolin K, Wong J, Doroshow JH, Forman S, Shibata S, Somlo G.

Biol Blood Marrow Transplant. 2012 Aug;18(8):1273-80. doi: 10.1016/j.bbmt.2012.01.021. Epub 2012 Feb 2.

44.

Design of an off-axis see-through display based on a dynamic phase correction approach.

Beuret M, Twardowski P, Fontaine J.

Opt Express. 2011 Sep 26;19(20):19688-701. doi: 10.1364/OE.19.019688.

PMID:
21996911
45.

Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.

Bourdeanu L, Twardowski P, Pal SK.

Clin J Oncol Nurs. 2011 Oct;15(5):513-7. doi: 10.1188/11.CJON.513-517.

PMID:
21951737
46.

A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.

Portnow J, Frankel P, Koehler S, Twardowski P, Shibata S, Martel C, Morgan R, Cristea M, Chow W, Lim D, Chung V, Reckamp K, Leong L, Synold TW.

Cancer Chemother Pharmacol. 2012 Feb;69(2):505-14. doi: 10.1007/s00280-011-1721-x. Epub 2011 Aug 18.

47.

Surface roughness analysis of hardened steel after high-speed milling.

Twardowski P, Wojciechowski S, Wieczorowski M, Mathia T.

Scanning. 2011 Sep-Oct;33(5):386-95. doi: 10.1002/sca.20274. Epub 2011 Aug 9.

PMID:
21830224
48.

A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.

Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN Jr.

Int J Clin Oncol. 2011 Oct;16(5):494-9. doi: 10.1007/s10147-011-0212-8. Epub 2011 Mar 23.

PMID:
21431345
49.

Critical appraisal of cabazitaxel in the management of advanced prostate cancer.

Pal SK, Twardowski P, Sartor O.

Clin Interv Aging. 2010 Dec 3;5:395-402. doi: 10.2147/CIA.S14570. Review.

50.

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial.

Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn DI, Gandara DR.

Urology. 2010 Oct;76(4):923-6. doi: 10.1016/j.urology.2010.04.025. Epub 2010 Jun 19.

Supplemental Content

Loading ...
Support Center